openheart.bmj17h
Global, regional and national burdens of cardiovascular disease attributable to secondhand smoke from 1990–2019: an age-period-cohort analysis
Background Over the past three decades, significant disparities in the global burden of cardiovascular disease (CVD) have ...
openheart.bmj17h
Phase 1 study of novel anti-platelet agent to overcome pharmacogenomic limitations of clopidogrel
Aims Clopidogrel is the most commonly prescribed thienopyridine as part of dual anti-platelet therapy for the treatment of ...
openheart.bmj17h
Association of blood pressure and left ventricular mass with subclinical coronary atherosclerosis
Background Left ventricular (LV) mass is closely associated with atherosclerotic heart disease, but the mechanisms are not ...
openheart.bmj17h
Efficacy and safety of anti-thrombotic therapy after surgical mitral valve repair: a scoping review
Background Mitral valve repair (MVr) is the gold standard treatment for degenerative mitral regurgitation, yet there is ongoing controversy regarding optimal anti-thrombotic therapy post-MVr. This ...